Aim: The co-existence of type 2 diabetes (T2D) with nonalcoholic fatty liver disease (NAFLD) significantly increases the prevalence of advanced fibrosis and end-stage liver disease, as well as cardiovascular disease risk and mortality. Fibrosis 4 (FIB-4) index has been described as a non-invasive marker to detect liver fibrosis, based on several laboratory texts (AST/ALT/Platelets) . This study aimed to explore the relationship between FIB-4 index and macroalbuminuria in patients with T2D and NAFLD.

Methods: This cross-sectional utilized data in Tibetan patients with T2D and NAFLD from 2020-2021. Patients were divided into two groups based on FIB-4 index (group 1: FIB-4<1.45; group 2: FIB-4≥1.45) . Reduced eGFR was defined as eGFR <60 ml/min per 1.73 m2 and macroalbuminuria was defined as urinary albumin/creatine ≥ 300 mg/g.

Results: A total of 362 patients were recruited. Clinical characteristics of subjects were showed in Table 1. In Multiple logistic regression analysis, compared to patients with FIB-4 <1.45, those with FIB-4 ≥ 1.45 were at a 2.26-fold (95% CI:1.08-4.73) for macroalbuminuria, after adjusted for age, gender, duration of T2D, BMI, LDL-C, HbA1c and hypertension. However, FIB-4 index was not associated with reduced eGFR (OR: 2.34, 95% CI: 0.89-6.18) .

Conclusions: Our finding showed that an increase in FIB-4 index was independently associated with macroalbuminuria in T2D patients with NAFLD.


C.Zhang: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at